PhoreMost Limited and C4X Discovery Holdings plc have signed a neurodegeneration drug discovery collaboration agreement. Combining the two companies’ technology platforms to validate novel targets, the initial focus will be on Parkinson’s disease. Under the terms of the agreement, PhoreMost’s next-generation phenotypic screening platform, SITESEEKER®, will be used to guide selection of novel targets identified by C4XD’s target identification platform, Taxonomy3®, and provide chemical starting...